Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma
Inhibition of the RNA translation factor, eIF4E, as a novel treatment strategy in Ewing Sarcoma
Dr. John Prensner, M.D., Ph.D. – The Regents of the University of Michigan, Ann Arbor, MI
Targeting ALT-Associated Vulnerabilities in Pediatric High-Grade Glioma
Targeting ALT-Associated Vulnerabilities in Pediatric High-Grade Glioma
Dr. Jihye Paik, Ph.D. – Weill Medical College of Cornell University, New York, NY
Dissecting CBFA2T3-GLIS2 Fusion-Driven Leukemogenesis and Therapeutic Resistance
Dissecting CBFA2T3-GLIS2 Fusion-Driven Leukemogenesis and Therapeutic Resistance
Dr. Brandon Hadland, M.D. – Fred Hutchinson Cancer Center, Seattle, WA
Dissecting Ewing Sarcoma On-Chip for Better Therapeutics
Dissecting Ewing Sarcoma On-Chip for Better Therapeutics
Dr. Yuan Gao, Ph.D. – Case Western Reserve University - School of Medicine, Cleveland, OH
Mapping Mitochondrial-localized mRNA Translational Rewiring in Radiation-resistant Pediatric DIPG
Mapping Mitochondrial-localized mRNA Translational Rewiring in Radiation-resistant Pediatric DIPG
Dr. Furqan Fazal, Ph.D. – Baylor College of Medicine, Houston, TX
Linking the Gut Microbiome to Chemotherapy Toxicity in Pediatric ALL
Linking the Gut Microbiome to Chemotherapy Toxicity in Pediatric ALL
Dr. Eran Elinav, M.D., Ph.D. – Weizmann Institute of Science, Israel
Deciphering mutually exclusive T-ALL and neurodevelopmental mutations in the ARD domain of the ZMIZ1 coactivator
Deciphering mutually exclusive T-ALL and neurodevelopmental mutations in the ARD domain of the ZMIZ1 coactivator
Dr. Mark Chiang, M.D., Ph.D. – The Regents of the University of Michigan, Ann Arbor, MI
Precision Epigenetic Therapies for Pediatric Burkitt Lymphoma
Precision Epigenetic Therapies for Pediatric Burkitt Lymphoma
Dr. Darko Barisic, Ph.D. – Weill Medical College of Cornell University, New York, NY
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Targeting oncogenic transcriptional programs in Juvenile Myelomonocytic Leukemia
Dr. Julia Maxson, Ph.D. – Oregon Health & Science University – OHSU, Portland, OR
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Cooperative mutagenesis driving pediatric pre-B cell leukemia
Dr. Abby Green, M.D. – Washington University, School of Medicine, St. Louis, MO
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dietary valine modulation to enhance therapies for high-risk T-ALL
Dr. Palaniraja Thandapani, Ph.D. – University of Texas M.D. Anderson Cancer Center, Houston, TX
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Targeting apoptosis to prevent cancer therapy-induced cardiovascular dysfunction in pediatric patients
Dr. Kristopher Sarosiek, Ph.D. – President and Fellows of Harvard College, Harvard T. H. Chan School of Public Health, Boston, MA
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Preclinical evaluation of omacetaxine as a novel therapeutic for ATRT
Dr. John Prensner, M.D., Ph.D. – University of Michigan Medical Center (Michigan Medicine), Ann Arbor, MI
Validating PRL2 as a New Therapeutic Target in T-ALL
Validating PRL2 as a New Therapeutic Target in T-ALL
Dr. Loretta Li, M.D. – Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Epitranscriptomic mechanisms of therapy resistance in high-risk neuroblastoma
Dr. Liron Grossmann, M.D. – The Sheba Fund for Health Service and Research, Israel
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
The Role of S100A8/A9-IL6R in B-ALL Chemoresistance
Dr. William Carroll, M.D. – New York University Grossman School of Medicine, New York, NY